Pharmacology of 1-(2-oxo-1-pyrrolidino)-4-(2-chloroethyl-methylamino)but-2-yne-HCl (DSO-16), I. Its central cholinomimetic and cholinolytic effects on mice.
D000480:Alkynes / Q000138:chemical synthesis / Q000494:pharmacology; D000698:Analgesia; D000818:Animals; D004336:Drug Antagonism; D004357:Drug Synergism; D005260:Female; D006591:Hexobarbital; D008297:Male; D008744:Methylamines / Q000138:chemical synthesis / Q000494:pharmacology; D051379:Mice; D009157:Myasthenia Gravis / Q000139:chemically induced; D009184:Mydriatics; D009538:Nicotine; D009539:Nicotinic Acids; D010276:Parasympatholytics / Q000494:pharmacology*; D010277:Parasympathomimetics / Q000494:pharmacology*; D010424:Pentobarbital; D010830:Physostigmine; D011760:Pyrrolidinones / Q000138:chemical synthesis / Q000494:pharmacology*; D014202:Tremor / Q000139:chemically induced
D000480:Alkynes; D008744:Methylamines; D009184:Mydriatics; D009539:Nicotinic Acids; D010276:Parasympatholytics; D010277:Parasympathomimetics; D011760:Pyrrolidinones; C003025:N-(4-(2-chloroethylmethylamino)-2-butynyl)-2-pyrrolidone; D009538:Nicotine; D010830:Physostigmine; D006591:Hexobarbital; D010424:Pentobarbital